Pembrolizumab Trial for Endometrial Cancer Reaches Primary Completion

A Phase 3 clinical trial evaluating pembrolizumab in combination with radiation therapy for newly diagnosed early-stage high-intermediate risk endometrial cancer reached its primary completion on 2025-12-30. The study, NCT04214067, is investigating whether adding the immunotherapy drug to standard radiation treatment reduces cancer recurrence.

Background

The trial is designed to assess the effectiveness of adding pembrolizumab, an immunotherapy drug, to the usual radiation treatment for patients with newly diagnosed stage I-II endometrial cancer. The goal is to determine if this combination is more effective than radiation therapy alone in reducing the risk of cancer recurrence.

Trial design

The study, NCT04214067, is a Phase 3 trial with an enrollment of 164 participants. It investigates the addition of pembrolizumab to radiation therapy for patients with Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, and Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8. The trial compares the combination of pembrolizumab and radiation therapy against radiation therapy alone.

What this means

The primary completion of this Phase 3 trial signifies a significant milestone in the study of pembrolizumab for early-stage endometrial cancer. While specific efficacy or safety results are not yet available, this completion indicates that the main data collection period for the primary endpoints has concluded. Future data releases will provide insights into the potential role of pembrolizumab in improving outcomes for patients with this condition.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04214067, titled "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer," was recorded with a primary completion date of 2025-12-30 on clinicaltrials.gov.